Fluoroquinolones: Mode of Action and Mechanism of Resistance

A middle-aged runner is prescribed ciprofloxacin for a urinary infection and, a week later, feels a sudden sharp pain in the back of the ankle: a partial Achilles tendon rupture. It is an uncommon but well-documented reaction that carries a regulatory black-box warning, and it captures why fluoroquinolones are both valued and used with care. They are powerful, broad-spectrum, orally absorbed antibiotics that kill bacteria by attacking the enzymes that manage bacterial DNA. Understanding that mechanism explains their wide spectrum, their concentration-dependent killing, the way resistance builds step by step, and the distinctive safety cautions that come with the class.

What are fluoroquinolones?

Fluoroquinolones are a class of bactericidal antibiotics that kill bacteria by inhibiting the enzymes that coil and uncoil bacterial DNA: DNA gyrase and topoisomerase IV. They are the fluorinated descendants of the original quinolone, nalidixic acid, and the added fluorine and other modifications gave them a much broader spectrum and better tissue penetration. Members include ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, norfloxacin, and gemifloxacin. Because they are well absorbed by mouth and penetrate tissues well, they can often treat serious infections with oral therapy.

Why fluoroquinolones matter

Fluoroquinolones cover a broad range of gram-negative bacteria (ciprofloxacin is notably active against Pseudomonas), atypical pathogens, and, for the later "respiratory" agents, the pneumococcus that causes community-acquired pneumonia. Their oral absorption makes them convenient for outpatient treatment of urinary, gastrointestinal, and respiratory infections. But rising resistance and a set of serious safety warnings, from tendon rupture to nerve and heart effects, have led authorities to recommend reserving them when safer options exist. Both the usefulness and the cautions follow from how they work.

Structure and classification

Fluoroquinolones share a bicyclic quinolone (or naphthyridone) core with a fluorine atom at position 6, which is the feature that separates them from the older, narrow quinolones. They are commonly grouped by generation, with the spectrum broadening at each step.

Mode of action of fluoroquinolones

Bacterial DNA is constantly being coiled and uncoiled during replication and transcription, and two enzymes manage that supercoiling: DNA gyrase (a type II topoisomerase) and topoisomerase IV. Fluoroquinolones bind these enzymes while they are bound to DNA and trap the enzyme-DNA complex at the moment the DNA strands are cut. The trapped complexes are converted into permanent double-strand breaks in the chromosome, which is lethal, so fluoroquinolones are bactericidal.

Which enzyme is the main target depends on the organism: DNA gyrase is the primary target in most gram-negative bacteria, and topoisomerase IV is the primary target in most gram-positive bacteria. Killing is concentration-dependent, so the higher the peak relative to the MIC, the more effective the drug.

Fluoroquinolones are the class that acts by inhibiting nucleic acid synthesis. Read this article to understand where this sits among the five mechanisms of action of antibiotics, and how it differs from the drugs that hit the cell wall or the ribosome.

Clinical uses

Fluoroquinolones are used for urinary tract infections and pyelonephritis, prostatitis, bacterial gastroenteritis and traveler's diarrhea, typhoid fever, community-acquired pneumonia and other respiratory infections (the respiratory agents levofloxacin and moxifloxacin), bone and joint infections, and as ciprofloxacin for anthrax and plague post-exposure prophylaxis. Because of resistance and safety concerns, guidance now favors reserving them for situations where the benefit clearly outweighs the risks.

Side effects and cautions

Fluoroquinolones carry several important warnings. The best known is tendinopathy and tendon rupture (classically the Achilles tendon), which is the subject of a black-box warning. They can also prolong the QT interval and cause arrhythmias, produce central nervous system effects (headache, dizziness, confusion, seizures), peripheral neuropathy, and disturbances of blood glucose, and they are associated with aortic aneurysm and dissection and with Clostridioides difficile infection. They are generally avoided in children and pregnancy because of concerns about developing cartilage. Like tetracyclines, their absorption is reduced by dairy, antacids, and iron because they chelate divalent and trivalent cations; see Tetracyclines for the same chelation caution.

Mechanism of resistance to fluoroquinolones

The ways bacteria resist fluoroquinolones are specific examples of the general mechanisms of antibiotic resistance: target modification, reduced accumulation (efflux and permeability), and target protection or drug modification carried on plasmids.

Target modification (the main mechanism). Point mutations in the genes for the target enzymes reduce fluoroquinolone binding. These mutations cluster in a region called the quinolone resistance-determining region (QRDR) of gyrA and gyrB (DNA gyrase) and parC and parE (topoisomerase IV). Resistance often builds stepwise: one mutation raises the MIC a little, and each further mutation raises it more, until the drug fails.

Reduced accumulation. Efflux pumps (such as NorA in Staphylococcus aureus and the AcrAB-TolC and Mex systems in gram-negatives) push the drug out, and reduced porin expression lowers entry, so less drug reaches the target.

Plasmid-mediated quinolone resistance (PMQR). Transferable genes add low-level resistance that can spread and help higher-level mutations emerge: qnr genes produce proteins that protect the enzyme from the drug, a variant acetyltransferase (aac(6')-Ib-cr) chemically modifies some fluoroquinolones, and plasmid-borne efflux pumps (qepA, oqxAB) expel them.

How to remember

The class by its name: the "-floxacin" suffix marks a fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin).

Which enzyme, which bug: gram-Negative to Gyrase, gram-Positive to topoisomerase IV. A simple hook is that gyrase is the gram-negative target and topoisomerase "four" is the target in the other group.

The safety triad plus one: Tendons, Ticker (QT), and Thinking (CNS), plus avoid in the very young because of cartilage. These are the cautions that come up most.

Where students get confused

DNA gyrase versus topoisomerase IV. Both are type II topoisomerases and both are fluoroquinolone targets, but gyrase is the primary target in gram-negatives and topoisomerase IV in gram-positives.

Quinolone versus fluoroquinolone. Nalidixic acid is the original narrow quinolone; adding a fluorine (and other groups) created the broad-spectrum fluoroquinolones. They are the same family, not different classes.

Not every fluoroquinolone fits every infection. Ciprofloxacin is strong against gram-negatives and Pseudomonas but is a poor choice for pneumococcal pneumonia; the "respiratory" fluoroquinolones (levofloxacin, moxifloxacin) are the ones that reliably cover the pneumococcus. Conversely, moxifloxacin achieves low urinary levels and is not used for UTIs.

Resistance builds in steps. A single QRDR mutation may only nudge the MIC; it is the accumulation of mutations (often helped along by low-level plasmid-mediated resistance) that produces clinical failure.

The dairy and antacid problem is real. Like tetracyclines, fluoroquinolones chelate calcium, magnesium, iron, and aluminum, so taking them with milk, antacids, or supplements sharply cuts absorption.

Key exam facts

References

1. Hooper DC, Jacoby GA (2016). Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harbor Perspectives in Medicine. 6(9): a025320.
2. Aldred KJ, Kerns RJ, Osheroff N (2014). Mechanism of quinolone action and resistance. Biochemistry. 53(10): 1565-1574.
3. Redgrave LS, Sutton SB, Webber MA, Piddock LJV (2014). Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends in Microbiology. 22(8): 438-445.
4. Katzung BG (ed.) (2021). Basic and Clinical Pharmacology. 15th edn. McGraw Hill.